Innovent Biologics
$96.25Change from previous close: −1.84%Absolute change: −$1.80
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- $167.85B
- Enterprise value
- $149.63B
- P/E (trailing 12 months)
- 120.3
- Forward P/E
- 38.1
- PEG
- 0.92
- Price/book
- 6.89
- Price/sales
- 10.7
- EV/EBITDA
- 83.0
- EV/revenue
- 9.53
Profitability and growth
- Gross margin
- 76.5%
- Operating margin
- 14.0%
- Net margin
- 7.8%
- ROE
- 7.0%
- ROA
- 2.2%
- Revenue growth (year over year)
- 44.8%
- Earnings growth (year over year)
- 42.9%
Financial health
- Total cash
- $20B
- Total debt
- $2.32B
- Debt/equity
- 0.11
- Current ratio
- 2.68
- Quick ratio
- 2.35
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $129.07
- Median price target
- $129.55
- High price target
- $149.92
- Low price target
- $94.30
- Analysts with a price target
- 29
- Consensus
- Strong buy
- Forward EPS
- $2.53
- EPS estimate, current year
- $1.42
Shares and trading
- Beta
- 0.25
- Average volume
- 13.71M
- Shares outstanding
- 1.74B
- Float
- 1.61B
- Institutional ownership
- 55.4%
- Insider ownership
- 6.2%